Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献64篇:

客户使用该产品的13个实验数据:

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MVzDfZRwfG:6aXOgRZN{[Xl? NHjyNogyOCCwTR?= MVO3NkBp NFX3[YRFVVOR MWnQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= MlHjNlQ6ODB6N{O=
HT-29 MYHDfZRwfG:6aXOgRZN{[Xl? NV\mNVJMOTBibl2= MnHKO|IhcA>? M4jaWWROW09? MlTuVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NVvKNoFVOjR7MEC4O|M>
HT-29 MlO3R5l1d3SxeHnjJGF{e2G7 MXOxNEBvVQ>? NWC5dY8yPzJiaB?= NGPucHFFVVOR M1\QbHBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NYLTbGtuOjR7MEC4O|M>
PC3 MnnET4lv[XOnIFHzd4F6 MV6xNFAhdk1? M1TEdFEhcA>? NHO5bGJFVVOR NIHYPFdRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NFHOfIQzOTl5OE[4Ny=>
PC3 M17ZZWtqdmG|ZTDBd5NigQ>? MnL6NVAxKG6P M{DxNFEhcA>? Mn[wSG1UVw>? MmrOSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NFnqVlQzOTl5OE[4Ny=>
PC3 NWq4eodMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jkOVEvPSEQvF2= M3XqWlEhcA>? NUXNbVFuTE2VTx?= NFXSdmdKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= MoflNlE6Pzh4OEO=
HEK293 NXLTWoh4TnWwY4Tpc44hSXO|YYm= NXLMSJpoOTByIH7N Mkj3PEBp MoHWSG1UVw>? MkHWTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P M2TNXVIyPTN7M{Cx
BT-20 NXHBbmd7U2mwYYPlJGF{e2G7 MXOyNEDPxE1? MWDEUXNQ Mk\lSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? MkPBNlE{PTN3NUG=
U937 Mn;PRY51cWKjY4TldolidCCDc4PhfS=> M{T2ZlUxKM7:TR?= NITvb5o1QCCq NEXHRY9FVVOR MYfJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? M1\Ud|IyOTR{MUC2
U937 MnKzRY51cWKjY4TldolidCCDc4PhfS=> MnflOVAh|ryP M3;rRVQ5KGh? NFrTdYdFVVOR MoDmSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? NXz4SnpVOjFzNEKxNFY>
U937 NXO2Tm14SW62aXLhZ5RmemmjbDDBd5NigQ>? NEH3WJM2OCEQvF2= NEW2c2k1QCCq M33mdmROW09? NUHGUWo6TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? MXOyNVE1OjFyNh?=
MCF-7 NFHaOWpCfXSxcHjh[5khSXO|YYm= MW[zNEBvVQ>? MoP3OEBp NYrpfYd2TE2VTx?= MXTJcoR2[2W|IHH1eI9xcGGpeR?= MnXSNlAxOjhzM{S=
U87MG NH\RS2JMcW6jc3WgRZN{[Xl? NVzKXnV3OSEQvF2= MkfEOkBp NGfHRlhFVVOR MmLKVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? MVKxPVg1QDRyNB?=
U87MG Ml3NT4lv[XOnIFHzd4F6 MWWxJO69VQ>? NIjuTJk3KGh? MnW4SG1UVw>? NYS3NG05WG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> Mo\KNVk5PDh2MES=
U87MG NGLXNWpMcW6jc3WgRZN{[Xl? NGrYPXEyKM7:TR?= NFexe5o3KGh? MX7EUXNQ NIC3W29Fd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NFzBfJgyQTh2OESwOC=>
U87MG NXqzbYF6U2mwYYPlJGF{e2G7 M4G3UFEh|ryP NEDqXWQ3KGh? MonRSG1UVw>? MVXEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NWnNcphTOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb NFnJSnhCfXSxcHjh[5khSXO|YYm= NYruWZJ3OC5{IN88US=> NUHPVndNOjRiaB?= M3OzPGROW09? NVTzOmhjUW6mdXPld{BifXSxcHjh[5k> M{nZWVE5OzlzOUS5
COS7 cells expressing EGFP-LC3 M1rpSmF2fG:yaHHnfUBCe3OjeR?= NFzsO5gxNjJizszN MmHBNlQhcA>? MonSSG1UVw>? MnvlTY5lfWOnczDheZRweGijZ4m= MUCxPFM6OTl2OR?=
H4 NXT6WoY4TnWwY4Tpc44hSXO|YYm= NUXnTWNpOC5{IN88US=> NWnwOJdlOjRiaB?= M2HYeGROW09? MmrHTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> NHTlfIgyQDB{NEW4OC=>
HeLa NVTH[25sTnWwY4Tpc44hSXO|YYm= Mn\KNVAxKG6P MX[zOkBp M3vadGROW09? MYrJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u NYfCZ2R7OTd3NkOzPFU>
HeLa NVy4UWJITnWwY4Tpc44hSXO|YYm= MVmxNFAhdk1? M1[5SlM3KGh? NXXOZYRJTE2VTx?= NUfZOmQ6UW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MYCxO|U3OzN6NR?=
HeLa NVjxU2llTnWwY4Tpc44hSXO|YYm= NYDneo5XOTByIH7N Mn[1N|YhcA>? M{nVO2ROW09? MYfJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= MkLzNVc2PjN|OEW=
SYF M1:1eGZ2dmO2aX;uJGF{e2G7 M1PwNVExOCCwTR?= MVmyOEBp Mn7rSG1UVw>? MX;JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NUfOXWx5OTd3NkOzPFU>
SYF MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonqNVAxKG6P MofONlQhcA>? NX;pd2w6TE2VTx?= MlLnTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= M1nGVlE4PTZ|M{i1
HEK293T NX3NbW5{SW62aY\pdoFtKEG|c3H5 M{TTXVEhdk1? NEjyb441KGR? NX\DOlBYTE2VTx?= M4Ho[2lv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N NEHZSmoyPzR6NUWwNS=>
HEK293T MmjHRY51cX[rcnHsJGF{e2G7 NXniUZl[OSCwTR?= NEHjTpA1KGR? MoG5SG1UVw>? Mn2yTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= MmfKNVc1QDV3MEG=
PBMC MYrGeY5kfGmxbjDBd5NigQ>? NV[5fYViOSCwTR?= NF;BZlYyPCCm NVi3dog{TE2VTx?= MYTS[YR2[2W|IFPDVlUh\GWwc3n0fS=> NGTFNmcyPzR6NUWwNS=>
PBMC MmL5SpVv[3Srb36gRZN{[Xl? NEPHRlgyKG6P NXj2fGI1OTRiZB?= M{jQdWROW09? NWDzOmlUTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? MWOxO|Q5PTVyMR?=
HEK293 cells MVvLbY5ie2ViQYPzZZk> M1jZeVUxKG6P NUfZ[olbPDVibXnu MlviSG1UVw>? M4HSbWlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? MXKxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc Mn;3SpVv[3Srb36gRZN{[Xl? M3XXN|ExOCCwTR?= MYG0JIg> MlXoSG1UVw>? NIr5Xo5KdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? NX2wN2dJOTdzMkiyOlI>
Human mixed lymphocyte M3TOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf3[oE1PSCwTR?= NH23WmNFVVOR MU\JR|UxRTFwNjDuUU4> MV[xOlE5PTh4NR?=
Lewis rat lymph node cells M2fPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfEXVFZPSEQvF2= MoHXSG1UVw>? MoTlTWM2OD1{Lk[g{txO NX7RN3ZXOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice NWSz[XV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNEBvVQ>? M4LtWFczKGh? M1KyfWROW09? M4\lZmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= M{L6[FExODJzOUS4
MRK-nu-1 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH0T5BGUUN3ME2wMlg1PSCyTR?= NXLOeVM2W0GQR1XS
OCUB-M MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7JW2FOUUN3ME21MlI1KHCP NVO0VFAzW0GQR1XS
SF539 M4DhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfkTFVKSzVyPUGxMlYheE1? MmDnV2FPT0WU
ES4 NV\MXI1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjwU2xKSzVyPUKxMlUheE1? MkK5V2FPT0WU
RL95-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFyNzDwUS=> NXvv[5FPW0GQR1XS
LC-2-ad MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fiNGlEPTB;NEKzJJBO NILBeplUSU6JRWK=
Daudi M3yyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Y[2lEPTB;NEO0JJBO NXTPU|BYW0GQR1XS
NTERA-S-cl-D1 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjKTWM2OD12NEOgdG0> Mn\6V2FPT0WU
OS-RC-2 M3XTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\yTGlEPTB;NkWyJJBO NUTQUnF[W0GQR1XS
VA-ES-BJ NEDaUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPJTmlrUUN3ME23NlMheE1? NYO0fG12W0GQR1XS
GR-ST MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XsZWlEPTB;OES2JJBO MV3TRW5ITVJ?
SW872 M4T0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XEdWlEPTB;OES2JJBO NGPoe41USU6JRWK=
NOS-1 M{HaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfBTWM2OD16N{GgdG0> NGfybVBUSU6JRWK=
MC116 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3iyR2lEPTB;OUi1JJBO M1TQ[nNCVkeHUh?=
NCI-H1355 MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\oTWM2OD1zLkCxJI5O MmPLV2FPT0WU
RPMI-8226 NFW0WXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLwTWM2OD1zLkG5JI5O NIL3OIdUSU6JRWK=
TE-15 NYLEellrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q2NWlEPTB;MT6zOkBvVQ>? NI\sfo9USU6JRWK=
Ramos-2G6-4C10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P2eGlEPTB;MT60OkBvVQ>? NITlUIhUSU6JRWK=
KU812 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjtTWM2OD1{LkCxJI5O MnrJV2FPT0WU
EW-1 M{Lse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zuOmlEPTB;Mj6xO{BvVQ>? MXHTRW5ITVJ?
KS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwNEWgcm0> NVHWXZZHW0GQR1XS
SK-LMS-1 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rieGlEPTB;Mj60PUBvVQ>? NYXBXWR{W0GQR1XS
TGBC1TKB NIC5bGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwNkmgcm0> MoTMV2FPT0WU
TE-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jCXWlEPTB;Mj63O{BvVQ>? MlHUV2FPT0WU
ETK-1 NW\jPXY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1naR2lEPTB;Mj64NkBvVQ>? NWS5bmI6W0GQR1XS
BE-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXPWGlKSzVyPUKuPVkhdk1? MXLTRW5ITVJ?
A3-KAW MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HFPWlEPTB;Mj65PUBvVQ>? NIiwWFZUSU6JRWK=
TE-10 NEe1cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O2b2lEPTB;Mz6zJI5O MXHTRW5ITVJ?
DOHH-2 NWjXSWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTNwM{Wgcm0> NEnx[5VUSU6JRWK=
ES6 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTNwNEOgcm0> NXi0bFA1W0GQR1XS
OPM-2 NW\0PXdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLLOm1iUUN3ME20MlE2KG6P NH3BelRUSU6JRWK=
SH-4 M1Tobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRwM{Sgcm0> NUDuW5BGW0GQR1XS
NB13 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;qRWlEPTB;ND6zOkBvVQ>? MUjTRW5ITVJ?
HUTU-80 M4XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK3TWM2OD12LkSyJI5O NFTCcZNUSU6JRWK=
CCRF-CEM MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTRwOUSgcm0> NXznVI1JW0GQR1XS
TGBC24TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHyNVRKSzVyPUWuOVEhdk1? MWPTRW5ITVJ?
697 M4S2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHnT5ZKSzVyPU[uNlghdk1? M1\C[HNCVkeHUh?=
J-RT3-T3-5 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwNE[gcm0> MnnhV2FPT0WU
KALS-1 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\xV|ZrUUN3ME22MlU3KG6P M3TmenNCVkeHUh?=
no-10 M{LjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHiyZpdKSzVyPUeuNlkhdk1? MYjTRW5ITVJ?
SK-NEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jMSWlEPTB;OD63PUBvVQ>? NXTxUGVUW0GQR1XS
L-540 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPNbZdKSzVyPUGwMlQzKG6P NGDPNZFUSU6JRWK=
JiyoyeP-2003 M1Ljbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFyLkm0JI5O NXi4N45NW0GQR1XS
HH MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjCPGRKSzVyPUGxMlM6KG6P MWTTRW5ITVJ?
SR MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHUTWM2OD1zMT60OUBvVQ>? M1jGT3NCVkeHUh?=
QIMR-WIL NYLWUHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFzLki1JI5O MlrLV2FPT0WU
A4-Fuk NFT2WVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF|LkGyJI5O NVvCO|FVW0GQR1XS
CESS NIi1O|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvnO5VKSzVyPUGzMlE{KG6P MlewV2FPT0WU
KE-37 NFHLWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPJTWM2OD1zNj6wO{BvVQ>? M{P4b3NCVkeHUh?=
SK-UT-1 NF;YcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF4LkixJI5O MmnUV2FPT0WU
SIG-M5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzuRpZEUUN3ME2xO{4zPSCwTR?= NVfBN497W0GQR1XS
HT NGHVOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fY[mlEPTB;MUeuOkBvVQ>? M3nXSXNCVkeHUh?=
DEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;OZmJiUUN3ME2xO{46QSCwTR?= MnO3V2FPT0WU
SK-PN-DW Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJyLkKzJI5O NITqO2NUSU6JRWK=
RPMI-8402 M1vDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v3bGlEPTB;MkGuO|chdk1? M3;FfXNCVkeHUh?=
RPMI-6666 M1LDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WzcWlEPTB;MkSuOFIhdk1? NEi0SYNUSU6JRWK=
NCI-H720 NH;UdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLoTWM2OD1{NT60NUBvVQ>? MYjTRW5ITVJ?
EW-16 NF7VVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PGXWlEPTB;Mk[uPFchdk1? Ml3hV2FPT0WU
BL-70 M3\PWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj5WmVWUUN3ME2yPE4{QCCwTR?= NIi4bFVUSU6JRWK=
SF126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW1WYZKSzVyPUOwMlM5KG6P NWLmSmNDW0GQR1XS
BC-1 M37HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1eyXmlEPTB;M{GuNlYhdk1? MkHkV2FPT0WU
MHH-PREB-1 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf5[W9KSzVyPUOyMlQ1KG6P MorXV2FPT0WU
A101D NFP1eWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i1cmlEPTB;M{KuOlIhdk1? MoD4V2FPT0WU
NMC-G1 NFuxV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vtS2lEPTB;M{OuOlchdk1? MWfTRW5ITVJ?
LB1047-RCC MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTN2Lk[5JI5O NIDP[ZVUSU6JRWK=
EM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXGTWM2OD1|OD61N{BvVQ>? MoLhV2FPT0WU
COLO-684 NULCOFJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDRTWM2OD1|OT64JI5O NYXSVnoyW0GQR1XS
Becker NWDGXlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVU3VRUUN3ME20NU4xPSCwTR?= NV7ROoxqW0GQR1XS
BL-41 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jTUWlEPTB;NEOuOlYhdk1? MnLNV2FPT0WU
MDA-MB-134-VI NGXsOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LkVmlEPTB;NESuNFIhdk1? NVPFVIl6W0GQR1XS
L-363 NV3E[2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPBUmp[UUN3ME20OE44OyCwTR?= M2X3NnNCVkeHUh?=
ECC4 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR2Lke4JI5O MmrGV2FPT0WU
A388 NFH2[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;VTWM2OD12ND64NkBvVQ>? M{\iTnNCVkeHUh?=
HEL NHHWWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxRmlEPTB;NEmuO|khdk1? NEjmSmxUSU6JRWK=
RKO MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzLTWM2OD13MD6yPUBvVQ>? MWjTRW5ITVJ?
KINGS-1 M1\4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTVzLkW1JI5O MXPTRW5ITVJ?
EB-3 NHviWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TxVWlEPTB;NUKuOlchdk1? MXLTRW5ITVJ?
ARH-77 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTV{Lkigcm0> NFzLUVNUSU6JRWK=
GCIY NHjS[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf4fYJoUUN3ME21N{41PiCwTR?= M{jvdXNCVkeHUh?=
NCI-H1304 NUm4Z21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTQelVUUUN3ME21O{4zOiCwTR?= NUnSU2xLW0GQR1XS
KARPAS-299 M4TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXlRZJKSzVyPU[xMlgzKG6P NV;3RYxIW0GQR1XS
IA-LM NFPsclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fFRmlEPTB;NkiuNVMhdk1? NHTkeohUSU6JRWK=
GI-1 NWfTVVROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[yTWM2OD15MD6zPUBvVQ>? M{HpNXNCVkeHUh?=
TE-11 NFniNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjJeZBKSzVyPUe3MlE4KG6P MkXKV2FPT0WU
LS-411N MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO2eIJKSzVyPUe3MlU4KG6P NE\PfFdUSU6JRWK=
no-11 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTh|LkK0JI5O MVjTRW5ITVJ?
MV-4-11 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXNTGJXUUN3ME24N{44OyCwTR?= MXfTRW5ITVJ?
BV-173 NUH2OIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrDNIdKSzVyPUizMlk4KG6P MkKxV2FPT0WU
CMK Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvKTWM2OD16ND6xOkBvVQ>? NHq3SYxUSU6JRWK=
LC4-1 M3TKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4SVZkUUN3ME24Ok44OiCwTR?= NYDTU3dmW0GQR1XS
COR-L279 NUfkO4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTh5LkK1JI5O MoHFV2FPT0WU
NCI-H209 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rpZmlEPTB;OEeuOFEhdk1? MUDTRW5ITVJ?
Raji NIi4dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPhTWM2OD16OT63NkBvVQ>? NFe5cZJUSU6JRWK=
LB996-RCC MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGruR|hKSzVyPUmzMlQ{KG6P NUDZWpBuW0GQR1XS
NCI-H526 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTl|LkW5JI5O NXvPOnJRW0GQR1XS
KGN M4Lwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTl4LkK5JI5O NHfYSYxUSU6JRWK=
MOLT-4 NEj1fJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2roU2lEPTB;OU[uO|khdk1? M3KxN3NCVkeHUh?=
PF-382 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXpTWM2OD17Nj63PUBvVQ>? MmTvV2FPT0WU
BC-3 M37nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG5blJjUUN3ME25PU4yQCCwTR?= MVrTRW5ITVJ?
KARPAS-422 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP0TWM2OD1zMEKuNFkhdk1? Mm\1V2FPT0WU
SBC-1 NYrzUZc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFyNz63OUBvVQ>? NUnUWmwyW0GQR1XS
LC-1F MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFyOD6wOUBvVQ>? NFTTZWdUSU6JRWK=
GB-1 NHXl[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DkVmlEPTB;MUC5MlAzKG6P MXPTRW5ITVJ?
SNB75 M{LiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy3U2pKSzVyPUGxPU43QSCwTR?= M1vz[nNCVkeHUh?=
BB65-RCC NIDjdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXnfnhKSzVyPUGxPU46OyCwTR?= NEjwd4xUSU6JRWK=
NCI-N87 M1rieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLyTWM2OD1zMkGuPVghdk1? NY\tXnZmW0GQR1XS
IST-MEL1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnPPJdKSzVyPUGyNk4{QCCwTR?= MmrOV2FPT0WU
HOP-62 M3jmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD0ZolUUUN3ME2xNlYvQDlibl2= NUD0e|hjW0GQR1XS
ACN NFK1eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF2Nj63OUBvVQ>? NF;5SlRUSU6JRWK=
DMS-114 NEfVeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF3MD62O{BvVQ>? Ml22V2FPT0WU
MLMA M2fVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzy[nNQUUN3ME2xOVkvQDhibl2= M2q4cHNCVkeHUh?=
HT-144 NWj3Row5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHOTWM2OD1zNkWuOFMhdk1? MVPTRW5ITVJ?
C2BBe1 NXmxN4E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXJTWM2OD1zNkeuO|Yhdk1? NEf5S49USU6JRWK=
L-428 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjqTWM2OD1zN{euO{BvVQ>? M3L4UXNCVkeHUh?=
DU-4475 M2m5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KzNmlEPTB;MUi3MlY5KG6P MmHzV2FPT0WU
CP67-MEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;kcXJKSzVyPUG5PU4{QCCwTR?= NWSwcllzW0GQR1XS
MEG-01 M1vnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OwbGlEPTB;MkCxMlk3KG6P Mnz6V2FPT0WU
IST-SL2 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJyOD62N{BvVQ>? NFLYVZRUSU6JRWK=
ES8 NHTMblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ{NT65OEBvVQ>? MYXTRW5ITVJ?
COLO-800 NFLtOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ|NT6yPEBvVQ>? M{mxd3NCVkeHUh?=
MFH-ino NVexRnRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ|NT64OEBvVQ>? NETyfHNUSU6JRWK=
OVCAR-4 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ|Nz6yOEBvVQ>? M4\qdXNCVkeHUh?=
PSN1 NY\qcHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnEVXk6UUN3ME2yOFIvPzFibl2= MnLiV2FPT0WU
EW-12 M{fYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPdmlEPTB;MkSzMlEhdk1? MljGV2FPT0WU
HCC1599 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ4MT60O{BvVQ>? MXTTRW5ITVJ?
SJSA-1 NVPFN2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ5MT60OkBvVQ>? NEfqWZdUSU6JRWK=
ST486 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W4ZmlEPTB;Mkm2MlE1KG6P M3P0PHNCVkeHUh?=
NOMO-1 NYDIXo44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELwbIlKSzVyPUOwNE4zOSCwTR?= M{DsPHNCVkeHUh?=
MN-60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXDVW9KSzVyPUOwOU4{OiCwTR?= MlzDV2FPT0WU
HCC1187 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknCTWM2OD1|MEeuNlUhdk1? NHfQ[WtUSU6JRWK=
SW982 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjIWFFKSzVyPUOxOE44PSCwTR?= Ml6yV2FPT0WU
LB647-SCLC NIPEPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT0eZB2UUN3ME2zNlgvPzFibl2= MmG3V2FPT0WU
HC-1 M{i0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zGWmlEPTB;M{O1MlUhdk1? NUHJcZpNW0GQR1XS
EHEB NVX2T|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO1NndXUUN3ME2zN|cvPTJibl2= NYnHVIdOW0GQR1XS
TUR M2Wy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTVTWM2OD1|NkOuPVUhdk1? MkTBV2FPT0WU
LU-139 NYDDO3VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PFOmlEPTB;M{e4MlAzKG6P MYXTRW5ITVJ?
NB1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\uTWM2OD1|OESuOFUhdk1? M2LpOHNCVkeHUh?=
BB30-HNC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXMTWM2OD1|OEiuN|Ihdk1? NE[5ZoFUSU6JRWK=
HAL-01 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjvZlNUUUN3ME2zPFkvOjZibl2= MXjTRW5ITVJ?
K5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTtSpNKSzVyPUSxNU4{PyCwTR?= MUXTRW5ITVJ?
MZ2-MEL NHXLRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zvPGlEPTB;NEGzMlY1KG6P MWHTRW5ITVJ?
RXF393 M2XXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O3b2lEPTB;NEG2MlQ2KG6P NVrq[XhzW0GQR1XS
NCI-H1648 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3RlVxUUN3ME20NVcvPTNibl2= MlXSV2FPT0WU
TE-12 NYjObnBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLPTWM2OD12M{SuNlYhdk1? MX3TRW5ITVJ?
EoL-1- MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTR|Nz65PEBvVQ>? NVizfFFqW0GQR1XS
JAR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTR|OD62NkBvVQ>? NVrX[2JjW0GQR1XS
DSH1 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR3OD65NUBvVQ>? MnvuV2FPT0WU
NCI-H187 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQWWlEPTB;NE[yMlgyKG6P M4H1ZnNCVkeHUh?=
HCE-4 NV\PZoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;1TWM2OD12N{euOlYhdk1? NInsVJFUSU6JRWK=
8-MG-BA NXrsVVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Da[WlEPTB;NUixMlUzKG6P MVXTRW5ITVJ?
KLE NGSzUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTV6NT6yJI5O NYntU4xHW0GQR1XS
KNS-42 NYTRRVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj6N4JKSzVyPUW4Ok45OSCwTR?= M{GxdHNCVkeHUh?=
MSTO-211H MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZyOT63OEBvVQ>? M4PabnNCVkeHUh?=
GDM-1 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn76TWM2OD14MUSuNFkhdk1? NYLEXlZDW0GQR1XS
TE-1 NFjaR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\GTWM2OD14NE[uNVIhdk1? MVvTRW5ITVJ?
BT-474 NEfrU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTZ2Nz6wOkBvVQ>? NGq3dHNUSU6JRWK=
KARPAS-45 NYfPXnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZ2Nz62JI5O M{frR3NCVkeHUh?=
MOLT-16 NUHH[lB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjteHlKSzVyPU[0O{46OyCwTR?= MX3TRW5ITVJ?
KURAMOCHI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqwTWM2OD14NUeuOVEhdk1? MYDTRW5ITVJ?
K-562 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr6eHFKSzVyPU[2PU42OSCwTR?= NGK3e2ZUSU6JRWK=
EKVX MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZ5Mj63NUBvVQ>? MlTyV2FPT0WU
GAK Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSxR4dEUUN3ME22O|UvOyCwTR?= M3vMTXNCVkeHUh?=
NCI-SNU-5 NXzkR|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPk[XVKSzVyPU[5NE4xOSCwTR?= NIjGWnRUSU6JRWK=
NCI-H2126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17MVmlEPTB;N{K2Mlg4KG6P NEH0VIFUSU6JRWK=
CTV-1 NFHUWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTjTWM2OD15NESuPUBvVQ>? M4rXfXNCVkeHUh?=
SW962 NIK1bnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn1TWM2OD15NEiuOFQhdk1? MmjsV2FPT0WU
MONO-MAC-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTd3Nj65N{BvVQ>? M3G2[3NCVkeHUh?=
NCI-H748 M{XNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrZbHo2UUN3ME23OVgvQTlibl2= NXjBV|dlW0GQR1XS
NCI-H524 M3HWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe1TWM2OD15OECuO|Mhdk1? MXHTRW5ITVJ?
LS-123 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mzWGlEPTB;N{m1MlY6KG6P MW\TRW5ITVJ?
NB7 M3nkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRThzND6xOEBvVQ>? MXXTRW5ITVJ?
LS-1034 NYLJRYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjuTWM2OD16MkiuPVghdk1? MnLrV2FPT0WU
TE-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7uTWM2OD16OEOuOVYhdk1? NXTZOFQxW0GQR1XS
A704 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7JTWM2OD16OUmuNVUhdk1? NFTVVFBUSU6JRWK=
TK10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH5TGJTUUN3ME25NVYvODNibl2= NXjreJdrW0GQR1XS
NCI-H345 NHP0VGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTl2Mz6yNkBvVQ>? NGDKW5hUSU6JRWK=
CGTH-W-1 NIjTclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTl2OD6xN{BvVQ>? NUH3S3RiW0GQR1XS
NCI-H510A NUnTW4dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTl6NT6xNkBvVQ>? MVXTRW5ITVJ?
NCI-H1963 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwMEOyPVIh|ryP NEL0Vo9USU6JRWK=
SCC-3 NXP2cWliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwMEO0NVQh|ryP M2TtSHNCVkeHUh?=
EW-11 NYfYZ5JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwMEi3OFMh|ryP MVLTRW5ITVJ?
CPC-N NEj2Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vi[mlEPTB;MT6wPFgh|ryP MVvTRW5ITVJ?
NCI-H1417 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwMUKyOkDPxE1? MXrTRW5ITVJ?
DG-75 M1rzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL5NnYzUUN3ME2xMlE3Ojh3IN88US=> MYLTRW5ITVJ?
HD-MY-Z Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3uTWM2OD1zLkG2OFE3KM7:TR?= MX;TRW5ITVJ?
ATN-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XJNWlEPTB;MT6yOlIxQSEQvF2= NXPKNI03W0GQR1XS
KM-H2 M4XXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED3[3BKSzVyPUGuNlY1ODhizszN NYCwVpE3W0GQR1XS
NCI-H2081 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrveohYUUN3ME2xMlI3PjN5IN88US=> NWfxd3hEW0GQR1XS
HL-60 NHrmUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\BXmlEPTB;MT6yOlk2QSEQvF2= MVfTRW5ITVJ?
DB NI\xTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37BNmlEPTB;MT6yO|I1OiEQvF2= MlS3V2FPT0WU
NCI-H1522 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjFTWM2OD1zLkK4PFg4KM7:TR?= Ml3ZV2FPT0WU
AM-38 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKwTWM2OD1zLkOwO|Ih|ryP MonIV2FPT0WU
NCI-H446 NGDaOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwM{KxNlEh|ryP MmS5V2FPT0WU
SU-DHL-1 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;LVopkUUN3ME2xMlMzQDBzIN88US=> MY\TRW5ITVJ?
NH-12 NVO3UYt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fL[2lEPTB;MT6zOlM4PCEQvF2= NFKybWZUSU6JRWK=
DMS-79 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGzd|BKSzVyPUGuN|Y5PjZizszN NV3ON3E5W0GQR1XS
NCI-H716 M4L4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwM{i5PFYh|ryP M2[xRXNCVkeHUh?=
ML-2 M2jH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvFN41zUUN3ME2xMlQyPTJ7IN88US=> NF\WZ2NUSU6JRWK=
NB10 NV22VIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSyVpN5UUN3ME2xMlQ3PjN{IN88US=> NEjTNHRUSU6JRWK=
ONS-76 NUHkNZFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTOcll5UUN3ME2xMlU{PTZ7IN88US=> MmLXV2FPT0WU
LOUCY MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37jW2lEPTB;MT61OFY2PyEQvF2= MnK5V2FPT0WU
SCLC-21H MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnkTWM2OD1zLkW4OVgzKM7:TR?= NFLSN5hUSU6JRWK=
TGW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwNkO5O|Uh|ryP MoDFV2FPT0WU
LXF-289 M{\uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrFTWM2OD1zLkezNlY5KM7:TR?= NUHpPVlNW0GQR1XS
BB49-HNC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzmcoZKSzVyPUGuO|M2QDZizszN MmDjV2FPT0WU
NCI-H747 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37FWmlEPTB;MT63OVM1PiEQvF2= MVfTRW5ITVJ?
LU-165 NFS5VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDMdnVbUUN3ME2xMlg1QTh4IN88US=> MVzTRW5ITVJ?
OMC-1 NF3SWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7uPXdKSzVyPUGuPVUxPjZizszN NFm2SYZUSU6JRWK=
RCC10RGB MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu2WVJKSzVyPUGuPVU5OTdizszN NHjGPZpUSU6JRWK=
SW684 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwOU[wPVkh|ryP NETEeYNUSU6JRWK=
TE-8 M1r5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMEW1OVkh|ryP M2L3fXNCVkeHUh?=
SK-N-DZ MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nNSWlEPTB;Mj6xN|I4PCEQvF2= NY\oS3l2W0GQR1XS
EVSA-T NGDi[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn22TWM2OD1{LkG3N|E2KM7:TR?= MYPTRW5ITVJ?
KASUMI-1 M3HPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwMUi4NVUh|ryP NFvMOZFUSU6JRWK=
NKM-1 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTGN4hYUUN3ME2yMlI2PDd{IN88US=> M{LMenNCVkeHUh?=
CAL-148 NHG2cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvoTWM2OD1{LkOzOlE1KM7:TR?= MlzpV2FPT0WU
NCI-H64 NUfZbIU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwM{SyN|Ih|ryP MW\TRW5ITVJ?
KNS-81-FD NF;XNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq3T3VKSzVyPUKuN|Y3OiEQvF2= M3zVdHNCVkeHUh?=
KM12 NXqwfJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;kcmlEPTB;Mj60NFg{QSEQvF2= NWrZWGh5W0GQR1XS
SW954 NWjOb5BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjU5JTUUN3ME2yMlQ4Pzd7IN88US=> NEjBR5BUSU6JRWK=
NCI-H1395 NEW5NXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;mR25yUUN3ME2yMlUzPjR3IN88US=> Ml24V2FPT0WU
DJM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK1fmdCUUN3ME2yMlYxPjNizszN MmLaV2FPT0WU
COLO-668 NGD0W4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzseYJmUUN3ME2yMlgzPjl3IN88US=> NWXNT2VbW0GQR1XS
NCI-H1436 NFLxcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwOEW2NVUh|ryP MUXTRW5ITVJ?
LB2241-RCC M1f6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLNSYFKSzVyPUKuPFY5OzlizszN MUHTRW5ITVJ?
GT3TKB NGPm[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DSOmlEPTB;Mj64PVA2PSEQvF2= MoO5V2FPT0WU
COLO-824 NIPj[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\yRWlEPTB;Mj64PVc3QCEQvF2= MlvOV2FPT0WU
ES1 M2DuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwOEm4O|kh|ryP NFPtSGFUSU6JRWK=
LB771-HNC MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV60XppCUUN3ME2yMlkxQTR4IN88US=> MlrVV2FPT0WU
GI-ME-N MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwMEC5NFQh|ryP M1nQfXNCVkeHUh?=
NALM-6 NF;GOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4V|ZrUUN3ME2zMlAxQTN|IN88US=> MV3TRW5ITVJ?
LU-134-A NWDKNnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvRTWM2OD1|LkC1OFI2KM7:TR?= NYHFeodjW0GQR1XS
DMS-153 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG5TWM2OD1|LkC1PFI1KM7:TR?= MYfTRW5ITVJ?
MZ1-PC MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNwMEmwO|gh|ryP M2e0enNCVkeHUh?=
NCI-H1155 NWWwPVM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDZTWM2OD1|LkGxOlEh|ryP NWfYWYVYW0GQR1XS
CAS-1 M3\lNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwMUO3NFch|ryP MVnTRW5ITVJ?
D-502MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTNwMUSzPUDPxE1? MnKzV2FPT0WU
NCI-H2141 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ZO2V4UUN3ME2zMlE4PDV{IN88US=> NVLTbG1jW0GQR1XS
NB6 NXHQbmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj4TWM2OD1|LkG4NlU6KM7:TR?= NW\HSJFpW0GQR1XS
NCCIT MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSyXnVKSzVyPUOuNlE5ODlizszN M3fIfXNCVkeHUh?=
NB69 M1K4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjPTWM2OD1|LkOxPFkyKM7:TR?= NX\ubpFQW0GQR1XS
JVM-2 NEHVXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q3NmlEPTB;Mz6zOlQ{OyEQvF2= NHn6fJpUSU6JRWK=
K052 MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPCd5lKSzVyPUOuN|c6PjhizszN MXzTRW5ITVJ?
HCC2157 M17DUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jR[2lEPTB;Mz61N|IzQCEQvF2= MlvkV2FPT0WU
KMOE-2 M1LYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGw[|BjUUN3ME2zMlU1OjR{IN88US=> NVLuS4ZmW0GQR1XS
SF268 NGDNVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNwN{G1OVQh|ryP Mnj0V2FPT0WU
CHP-126 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrCZoxKSzVyPUOuO|Y1PThizszN NV3CeFlxW0GQR1XS
CP66-MEL NH7JRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrVZ4xKSzVyPUOuO|kxQTRizszN M3ThcHNCVkeHUh?=
NCI-H69 NI\YNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxTWM2OD12LkCxPVM3KM7:TR?= NXrKUGw6W0GQR1XS
A253 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TNbmlEPTB;ND6wNlExOSEQvF2= MWHTRW5ITVJ?
NB14 M3H6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;qOGlEPTB;ND6xNFQ4QSEQvF2= Ml;nV2FPT0WU
NCI-H1694 NGmxV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD5ZldKSzVyPUSuNVMyOTJizszN NHrUflhUSU6JRWK=
NCI-H2196 NULlWZRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7nVYVRUUN3ME20MlE4OTZ7IN88US=> M{TDT3NCVkeHUh?=
TE-9 NIrrNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwMUe1PFIh|ryP NHTKOWtUSU6JRWK=
D-283MED M4nvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL6Rox1UUN3ME20MlE5QDRizszN M3jMeXNCVkeHUh?=
OCI-AML2 NEfTeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRwMUm0PFkh|ryP NIT4RpRUSU6JRWK=
D-263MG M1XvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW2bHRUUUN3ME20MlIzQTZzIN88US=> NEnybFJUSU6JRWK=
MPP-89 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vGcWlEPTB;ND6yO|MxPCEQvF2= NYXRRoVlW0GQR1XS
LAMA-84 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XPUWlEPTB;ND6zNFQzOSEQvF2= NUW0WmJSW0GQR1XS
LB373-MEL-D NYPyT29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTpTWM2OD12LkO2O|g6KM7:TR?= NH7Gb5BUSU6JRWK=
UACC-257 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HFeWlEPTB;ND6zPVU{PCEQvF2= NGjMZ3ZUSU6JRWK=
MC-CAR NYezOGF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH3TWM2OD12LkSzPVkh|ryP MnqyV2FPT0WU
COLO-320-HSR NHflV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHB[4lKSzVyPUSuOFQ1OjdizszN NHPDNXpUSU6JRWK=
P30-OHK NFW3R|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTRwNk[1PFEh|ryP MWTTRW5ITVJ?
UACC-812 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TGWmlEPTB;ND62PVE3OSEQvF2= NULSTWlOW0GQR1XS
CTB-1 NG\4dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PMOGlEPTB;ND63NVU2PSEQvF2= NHnXXGRUSU6JRWK=
ALL-PO M2iwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwOESwO|ch|ryP MYDTRW5ITVJ?
SK-MEL-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzLTWM2OD12Lki2PVU2KM7:TR?= NV\3bFZvW0GQR1XS
TC-YIK NXrBS2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTRwOUe5OFIh|ryP NUW4TZV2W0GQR1XS
NCI-H1882 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1W2lEPTB;NT6wNlAxOSEQvF2= Ml3sV2FPT0WU
MHH-CALL-2 M4PBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnFV3dGUUN3ME21MlA2ODR{IN88US=> MlHYV2FPT0WU
U-87-MG NV\0OZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTVwMEm0OlYh|ryP NWjnc|EzW0GQR1XS
NCI-H1092 M2roRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HoemlEPTB;NT6yOlU2PSEQvF2= MYLTRW5ITVJ?
TE-441-T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnLTWM2OD13LkK3PFIh|ryP MXvTRW5ITVJ?
SK-MEL-1 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OxXGlEPTB;NT6yPVA1PCEQvF2= MWTTRW5ITVJ?
EW-22 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwMkm0OlYh|ryP M1LsTHNCVkeHUh?=
MZ7-mel M{jjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDKTWM2OD13LkSwOlkyKM7:TR?= Mm\TV2FPT0WU
LP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwNEGyPVEh|ryP M3HCXnNCVkeHUh?=
NCI-SNU-16 NIjBdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i1cmlEPTB;NT62OFA4PCEQvF2= NF3oTYtUSU6JRWK=
LU-65 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XrdmlEPTB;NT63OlM4OyEQvF2= NUDwTI5tW0GQR1XS
CW-2 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LZU2lEPTB;NT64OVk2QSEQvF2= MWLTRW5ITVJ?
WSU-NHL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTVwOUWxO|Qh|ryP Mof1V2FPT0WU
IST-MES1 NIT1NnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwOUW0OFMh|ryP NUn6cYltW0GQR1XS
U-266 NH;kPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV34OFF7UUN3ME21Mlk5OjB{IN88US=> NW[wU2NrW0GQR1XS
TALL-1 NFr0dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTHTWM2OD14LkG0Olg5KM7:TR?= NFnoWpNUSU6JRWK=
Calu-6 M4P1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZwMUWzNVYh|ryP MXPTRW5ITVJ?
MMAC-SF MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwMUi1OVYh|ryP NWfwe5NTW0GQR1XS
NCI-H82 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTZwMkC0PFkh|ryP NYWzVlV7W0GQR1XS
RS4-11 NGP4[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTZwMkW4PVch|ryP MX7TRW5ITVJ?
SNU-C2B MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK0TWM2OD14LkSwPVY6KM7:TR?= NH;pN|ZUSU6JRWK=
BOKU NEnnVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HIc2lEPTB;Nj60O|U6PyEQvF2= MXPTRW5ITVJ?
C8166 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXDTWM2OD14LkW1PVEzKM7:TR?= M2rqc3NCVkeHUh?=
D-247MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLUTlB4UUN3ME23MlA1OzR5IN88US=> Mnq0V2FPT0WU
EW-18 NGrRe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HXcGlEPTB;Nz6wO|I6OiEQvF2= NVLaU|lQW0GQR1XS
KG-1 NX[0cVBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jBfWlEPTB;Nz62Nlc{QCEQvF2= NYTsbVVSW0GQR1XS
REH MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHflZmRKSzVyPUeuOlgyODlizszN MXjTRW5ITVJ?
U-698-M MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTdwOESzNVUh|ryP M1L2[nNCVkeHUh?=
KP-N-RT-BM-1 NHnpSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiWmlEPTB;Nz65N|AzQSEQvF2= NIHC[pNUSU6JRWK=
MS-1 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jpNmlEPTB;Nz65OlA1OSEQvF2= NVjUNmdOW0GQR1XS
SNU-C1 M3\afmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTdwOUixPVIh|ryP MkLLV2FPT0WU
SK-MM-2 M4DxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfwU4tKSzVyPUiuNlYxPjVizszN NIK5WZlUSU6JRWK=
LAN-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe3[WtKSzVyPUiuN|AxODFizszN MYjTRW5ITVJ?
NEC8 NF;vVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRThwM{C2PVEh|ryP MkCzV2FPT0WU
NCI-H1770 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\RTWM2OD16LkO4NFAzKM7:TR?= Ml7qV2FPT0WU
D-336MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2ybGpFUUN3ME24MlQxOTF4IN88US=> NEiwOWNUSU6JRWK=
COLO-829 NVHGVoVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKyflc5UUN3ME24MlQ5QDd7IN88US=> NFfscWRUSU6JRWK=
LS-513 NYLIPZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnrTWM2OD16LkW5OVk6KM7:TR?= MX3TRW5ITVJ?
YT MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrVTGFwUUN3ME24MlYzPDJ5IN88US=> NHvNZ2tUSU6JRWK=
EW-24 NGDnUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRThwN{[1OEDPxE1? M{XSbnNCVkeHUh?=
IST-SL1 M{LSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jUOWlEPTB;OD64OlU1OyEQvF2= MljlV2FPT0WU
CA46 M3jP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRThwOUWwPVgh|ryP MWHTRW5ITVJ?
NCI-H1838 NEPmS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjCRXA2UUN3ME24Mlk5PjB{IN88US=> MmXFV2FPT0WU
NCI-H719 M3PzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnSTWM2OD17LkK1Nlc6KM7:TR?= Mlf0V2FPT0WU
HCE-T M2LSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m5[mlEPTB;OT6zNFg2OSEQvF2= M1XSUHNCVkeHUh?=
A498 NWr1OnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTlwM{[xNlQh|ryP NWqxXmRzW0GQR1XS
LB831-BLC NVfMSnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwN{[1NlEh|ryP NXSzbmpyW0GQR1XS
SKM-1 M2Lhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TyfWlEPTB;OT64OVk3OyEQvF2= MV\TRW5ITVJ?
THP-1 NHjMXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPSTWM2OD17Lkm2PVE5KM7:TR?= NGTNPHdUSU6JRWK=
SHP-77 NEX6VIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVcXJKSzVyPUGwMlQxPyEQvF2= NFToV5NUSU6JRWK=
EW-3 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFyLk[yPFkh|ryP NVjCZXVmW0GQR1XS
KY821 NXf3S3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\kTWM2OD1zMD63OlMh|ryP MYrTRW5ITVJ?
NCI-SNU-1 M1v5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;zd2lEPTB;MUGuNFIyPyEQvF2= NVzURoxOW0GQR1XS
HCC2218 M{LHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3VpJ3UUN3ME2xNU4{QTh4IN88US=> MnjPV2FPT0WU
IM-9 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO5TWM2OD1zMT61NVA3KM7:TR?= NU[xUotVW0GQR1XS
NCI-H889 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPtTWM2OD1zMT61N|E{KM7:TR?= M1vhdnNCVkeHUh?=
HDLM-2 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW3RZFKSzVyPUGyMlQyPTlizszN NGLS[YVUSU6JRWK=
LB2518-MEL NHe1TG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrZVYdbUUN3ME2xNk43QDF3IN88US=> NYDiXpZRW0GQR1XS
NCI-H23 NHK5c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPENVFKSzVyPUGzMlI1OjVizszN MoPjV2FPT0WU
NB17 M3rWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr5cmtKSzVyPUGzMlQ2PzlizszN Mo\qV2FPT0WU
NCI-H322M NGGzXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m1S2lEPTB;MUSuOFA3QCEQvF2= MljnV2FPT0WU
SUP-T1 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGyPGhKSzVyPUG0MlQyOyEQvF2= MVHTRW5ITVJ?
ES3 NHmybJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF3LkC3NFMh|ryP MljnV2FPT0WU
ES5 M4LkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1SYFIUUN3ME2xOU4xPzh5IN88US=> M4fwRXNCVkeHUh?=
NCI-H1650 M3zITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vv[GlEPTB;MUWuOFk4QSEQvF2= M{XEN3NCVkeHUh?=
NCI-H226 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTqNZBKSzVyPUG1Mlg4PjhizszN MUHTRW5ITVJ?
COR-L88 NF;2ZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrldGVKSzVyPUG2MlMyPCEQvF2= NUntO|gxW0GQR1XS
SCC-15 NWDBW4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF4LkO4Olkh|ryP NV6wXJNZW0GQR1XS
GOTO MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4LkS3PVMh|ryP MYnTRW5ITVJ?
SIMA M4j6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDCcplXUUN3ME2xOk41QDB{IN88US=> M1XpN3NCVkeHUh?=
NCI-H1299 M3ztfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Toe2lEPTB;MUeuNVU6OSEQvF2= M4PVS3NCVkeHUh?=
NCI-H1581 M{nocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Yco1KSzVyPUG3MlQzOTlizszN M{jNSnNCVkeHUh?=
MHH-NB-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\XTWM2OD1zNz65Olg{KM7:TR?= M1m0bHNCVkeHUh?=
MFM-223 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPZTWM2OD1zOD6wOVM5KM7:TR?= M2i4OnNCVkeHUh?=
ES7 NEnZdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHJSVdJUUN3ME2xPE42PDNzIN88US=> NXziUJlnW0GQR1XS
JVM-3 M1Hz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVizWIlUUUN3ME2xPE44OTdizszN M{DxPHNCVkeHUh?=
RL NVXlTIhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP5[o9xUUN3ME2yNE4{QDhizszN MYjTRW5ITVJ?
EC-GI-10 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJzLkKwOFEh|ryP M3;pTHNCVkeHUh?=
LNCaP-Clone-FGC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rmNWlEPTB;MkGuOlc3QCEQvF2= MX\TRW5ITVJ?
IMR-5 M3K1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGixS|lKSzVyPUKxMlg1QTRizszN MmD2V2FPT0WU
KP-N-YS M{fPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJzLki3OUDPxE1? M1nyeHNCVkeHUh?=
Mo-T M1Tu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJ{LkKxPFUh|ryP NWnuemZOW0GQR1XS
NCI-H128 MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j6bGlEPTB;MkOuOVg2OyEQvF2= MkniV2FPT0WU
RH-1 M1vUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nEOGlEPTB;MkOuO|g3PiEQvF2= MY\TRW5ITVJ?
NCI-H2171 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLpSmJxUUN3ME2yOE4zPDh3IN88US=> M2C3NHNCVkeHUh?=
RPMI-8866 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzHeWVCUUN3ME2yOk44PDJizszN MUTTRW5ITVJ?
SK-N-FI M1X2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrn[2VKSzVyPUK3MlM5OTFizszN NIi4OY1USU6JRWK=
LOXIMVI NUHSWllmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXoR|VnUUN3ME2yO{45ODVzIN88US=> MYjTRW5ITVJ?
P31-FUJ MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DIXmlEPTB;M{GuOVM4PCEQvF2= Ml7IV2FPT0WU
KMS-12-PE MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Tzc2lEPTB;NEmuOVMxOiEQvF2= NFfDTW9USU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID